Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. The company is headquartered in Waltham, Massachusetts and currently employs 87 full-time employees. The company went IPO on 2016-04-07. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
Follow-Up Questions
Spyre Therapeutics Inc 'in CEO'su kimdir?
Dr. Cameron Turtle 2023 'den beri şirketle birlikte olan Spyre Therapeutics Inc 'in Chief Executive Officer 'ıdır.
SYRE hissesinin fiyat performansı nasıl?
SYRE 'in mevcut fiyatı $22.47 'dir, son işlem günde 0% decreased etti.
Spyre Therapeutics Inc için ana iş temaları veya sektörler nelerdir?
Spyre Therapeutics Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 12 analist Spyre Therapeutics Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 10 güçlü al, 6 al, 2 tut, 0 sat ve 10 güçlü sat içermektedir
